News
ASCO GU 2022: Phase 1/2 Study of ARV-110, an Androgen Receptor PROTAC Degrader, in Metastatic Castration-Resistant Prostate Cancer (UroToday.com) ... Further, of 7 patients with AR T878A/S and/or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback